Editor of Blood reviews a very bloody movie

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Do all the bloody scenes from some of last year’s top-rated movies-There Will Be Blood, No Country for Old Men, Sweeney Todd-suggest that the American Society of Hematology is doing product placement?

Do all the bloody scenes from some of last year’s top-rated movies-There Will Be Blood, No Country for Old Men, Sweeney Todd-suggest that the American Society of Hematology is doing product placement? Cynthia E. Dunbar, MD, editor-in-chief of Blood, says no. “But we’d be happy if anyone ever had a hematologist in a movie,” she wrote in a review of Oscar winner No Country for Old Men for the Sunday newspaper supplement USA Weekend (March 28-30, 2008, page 11).

The magazine invited her to review the movie upon its DVD release. Dr. Dunbar, a hematologist at the National Institutes of Health, said the violence in the film didn’t bother her, and, like so many others, she thought “the last quarter of the movie was confusing.” At the end of the review, Dr. Dunbar did manage to insert a product placement for the study of blood. “Even though blood may not seem aesthetically pleasing shooting out of people, under the microscope, it’s very visual, especially if you stain the cells with different dyes,” she wrote.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content